When cancer is diagnosed, finding treatment options is the top priority
OncoTarget® Series is our comprehensive genomic profiling solution to identify targeted immunotherapies for advanced cancers– solid tumors or leukemias.
Learn about our newly launched, FDA cleared, 500-gene panel OncoTarget® 500
OncoTarget® Series Test Menu
OncoTarget® 500
FDA cleared gene panel testing
OncoTarget® Myeloid68
An NGS-Based Test For Myeloid Leukemia
OncoTarget® Liquid
Hematology Molecular Panel
Hematology FISH Panel
Immuno Profile Panel
Your confidence is found within OncoTarget’s
multi-technology platform
MSI and single mutations
Sample Collection
Sample Processing
Results
GoPath® Diagnostics Launches FDA-Cleared CGP Test under OncoTarget® 500
#ASCO22 week is here and we are excited to announce the release of our FDA-Cleared CGP Test under OncoTarget® 500.

Visit us in booth #28109 on June 4-6 between 9:00 AM–5:00 PM each day and learn how this CGP solution will help advance cancer treatments by identifying genomic targets for both targeted therapy and immunotherapy.
Stay connected